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NATIONAL
UPDATE:
New Cancer 
Therapies
By K en n e th  O lden  
an d  S an dra  L. W h ite
Considerable progress in the treat­ment or management of cancer has been made since the passage of the 
National Cancer Act in 1971. That act 
created the National Cancer Program 
which encompasses all activities supported 
by the National Cancer Institute and can­
cer-related activities sponsored by bureaus, 
institutes, and divisions of the National 
Institutes of Health. This formalized com­
mitment of resources to the eradication of 
cancer resulted in a dramatic expansion and 
diversification of experimental approaches 
to control this dreadful disease. It also has 
led to great expectations fueled by media 
over-interpretation of periodic announce­
ments of important discoveries and break­
throughs. However, a number of cancers 
are now curable, and the survival and 
quality of life of individuals with incurable 
cancers have remarkably improved.
While some cancers are curable with 
surgery alone, or in combination with 
chemotherapy and/or radiotherapy, these 
conventional methods of treatment have 
almost reached their limits of effectiveness 
with a cure rate of approximately 50 
percent. Therefore, the development of 
new and more effective therapies is crucial 
if we are to conquer this dreadful disease.
One of the most distinctive, yet disturb­
ing, characteristics of cancer is its propen­
sity to invade or spread (a process called 
metastasis) to various organs.
While the uncontrolled growth of benign 
or non-malignant tumors may occasionally 
be fatal if vital organ functions are impaired, 
more frequently the principal cause of 
morbidity and death is due to the spread of
the disease from the original or primary site 
to another healthy location within the body. 
Therefore, if spreading could be prevented, 
cancer could be controlled and, for the most 
part, cured.
The current challenges facing cancer 
researchers are: (i) to develop therapeutic 
plans to either prevent cancer from spread­
ing or the growth of secondary tumors 
following the dissemination of cells from the 
primary tumor, and (ii) to develop more 
sensitive methods for the detection of 
malignant growths long before they be­
come life-threatening or clinically man­
ifested. Cancer researchers are hopeful that 
the current developments using biological 
response modifiers, e.g. interferon and 
interleukin-2, and monoclonal antibodies 
will be sufficient to meet this challenge.
Articles debating the success of clinical 
trials utilizing interferon and interleukin-2 
appear frequently in major newspapers and 
magazines. While there are some reasons to 
be optimistic that these agents will prove to 
be effective for the treatment of some 
cancers, e.g. melanoma (a type of skin 
cancer) and renal cell carcinoma (the most 
common malignancy of the kidney), there is 
no justification for their being heralded, in 
some quarters, as “magic bullets” or “cure- 
alls” for cancer. Fueled by extravagant 
claims, on one hand, and skepticism on the 
other, cancer patients and their families are 
often confused.
This article will summarize the results of 
clinical trials utilizing interferon and inter- 
leukin-2 so that those facing this disease 
can better understand the debate and make 
more intelligent decisions about whether to 
participate in clinical trials involving the 
administration of these cancer therapies.
ADOPTIVE IMMUNOTHERAPY. This 
procedure involves the removal of some of the 
patient’s white blood cells or lymphocytes 
and treating them with a protein molecule 
called interleukin-2. This protein belongs to 
a family of molecules called lymphokines 
which are made by certain white blood cells 
in the body. However, as a result of modern 
techniques in biogenetic engineering, inter- 
leukin-2 now can be produced in large 
quantities for clinical use.
When interleukin-2 is incubated with the 
patient’s white blood cells, it activates a 
special group of the white blood cells called 
“killer cells” and makes them much more 
effective in selectively killing cancer cells. 
The interleukin-2 or lymphokine-activated 
“killer cells” are re-infused, along with 
sufficient new quantities of interleukin-2, to
keep the activated “killer cells” dividing in 
the cancer patient and thus available to kill 
cancer cells.
The first results with interleukin-2-acti- 
vated killer cells were spectacular. For 
example, researchers at the National Can­
cer Institute reported that they shrunk 
tumors in 44 percent of the patients with 
skin, colon, kidney and lung cancers. This 
was an impressive finding since these can­
cers are least responsive to chemotherapy. 
In contrast, ongoing studies at six other 
research centers, using the same pro­
cedure, are reporting response rates be­
tween 10 to 20 percent.
Additionally, adoptive immunotherapy is 
a very complex treatment to administer, 
and the present treatment regimen can be 
highly toxic, causing anemia, fever, fluid 
retention, nausea and respiratory prob­
lems. There also have been a number of 
infections caused by contamination of the 
white blood cells during treatment with 
interleukin-2 in the laboratory.
INTERFERON. Interferon, like inter­
leukin-2, is a natural protein product of 
white blood cells that acts by stimulation of 
the patient’s immune system. A few years 
ago, it was widely discussed as the new 
miracle drug for the treatment of cancer, as 
interleukin-2 is today. Yet the high expecta­
tions have been largely unrealized. Inter­
feron is now primarily used to treat a very 
rare form of cancer call “hairy cell” leuke­
mia. Indeed, it has been shown to reduce 
the tumor burden in more than 90 percent 
of patients with this particular cancer. It is 
also effective against lymphoma (cancer of 
the lymphoid tissue), but has not proved to 
be very useful for the treatment of most 
cancers when administered alone.
Even in the case of “hairy cell” leukemia, 
the number of complete cures is low and all 
patients treated still possess residual “hairy 
cells” in the bone marrow, which suggests 
that they will eventually relapse. Therefore, 
it is unlikely that “hairy cell” leukemia will 
be cured with interferon unless adminis­
tered in combination with another treat­
ment method.
MONOCLONAL ANTIBODIES. Mono­
clonal antibodies are highly specific biolog­
ical agents, created by cell fusion tech­
niques. They have proven to be remarkably 
versatile tools in many areas of biological 
research and clinical medicine. Antibodies 
are proteins produced by white blood cells, 
called B-lymphocytes, in response to a 
foreign substance that invades the body.
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Antibodies naturally participate in the com­
plex series of events, called the immune 
response, which comes into play when a 
person’s health is threatened by infectious 
or foreign agents, such as viruses or bacte­
ria or cancer. Monoclonal antibodies are 
more highly discriminating than conven­
tional antibodies, hence their effectiveness 
in differentiating between normal versus 
cancer cells which may have similar charac­
teristics. Cancer researchers have taken 
advantage of this high degree of specificity 
of monoclonal antibodies to selectively kill 
cancerous cells without harming healthy 
cells. Most drugs currently used in chemo­
therapy lack this selectivity.
Monoclonal antibodies are used in a 
variety of ways in cancer therapy. They can 
themselves directly attack or kill tumor 
cells. They can serve as vehicles for target­
ing toxic drugs or radioactive substances to 
tumors. The concept of “targeting” is 
analogous to a missile (the antibody) which 
is “armed” with nuclear weapons (the drug 
or radioactive substance).
By taking advantage of the fact that 
tumor cells are different from normal 
healthy cells, one can design a monoclonal 
antibody “missile system” that can selec­
tively destroy tumor cells. For a cure to be 
effected, larger doses of drug or radioac­
tivity must be delivered to the tumor than to 
the surrounding healthy tissue.
In diagnostic radiology, physicians are 
utilizing monoclonal antibodies to help 
locate tumor cell masses in the body. Such 
cancer imaging with monoclonal antibodies 
constitutes an exciting new approach 
that is broadly applicable to solid tumors.
In addition, the development of highly 
purified monoclonal antibodies has made it 
possible to passively immunize patients 
against various cancers or other infections. 
In fact, some researchers are producing 
“custom-designed” monoclonal antibodies 
against a specific patient’s cancer. This is 
based on the rationale that cancer is such an 
individualized disease that even the same 
cancer is so different in different individuals 
that individualized therapy may be re­
quired.
One of the major problems limiting the 
clinical usefulness of monoclonal antibody 
therapy has been the poor expression of 
antigens (molecules that interact with anti­
body) unique to human tumor cells. As is 
often the case, it is the level of expression 
rather than the absolute absence of an 
antigen that differentiates tumor cells from 
normal cells. While technical problems are
Cancer Research 
At Howard University
T he Howard University Cancer Center is the site of some promising research aimed at controlling the spread of cancer. One team of investigators [Kenneth Olden, Sandra L. White and 
Martin J. Humphries] is attempting to find ways to control cancer by 
using agents which prevent the spread of cancerous cells through the 
bloodstream. The potential for therapeutic success of this kind of 
strategy appears to offer marked improvement over the random, 
semi-empirical screening approaches used in the past.
Before embarking on their current research project, the inves­
tigators considered the following questions:
■ Under what circumstances might such agents be utilized for the 
treatment of cancer patients?
■ Will such medication cure the patient or prolong his or her life 
even though a complete cure is not achieved?
■ What chemical and biological characteristics should such drugs 
have to ensure that they are not toxic to humans, and that they are not 
rapidly removed or destroyed so that they remain in the body long 
enough to be effective?
■ Are such drugs likely to be effective with minimal impairment in 
the quality of life?
■ Realistically, is the technology available for the commercial 
production of such drugs at a cost society can afford?
At present, the three Howard researchers are utilizing two 
experimental approaches to prevent the spread or growth of tumors at 
secondary sites, such as the lung.
One approach involves the oral administration of a naturally- 
occurring agent called swainsonine. The investigators have found that 
swainsonine enhances the capacity of the host immune system to 
combat cancer. As such, they have classified it as a biological response 
modifier similar to interferon and interleukin-2.
The second approach involves the injection of a small molecule 
consisting of five amino acids (glycine-arginine-glycine-aspartic acid- 
serine) — which is called a pentapeptide — directly into the 
bloodstream. This specific pentapeptide inhibits the spread or 
metastasis of cancer by preventing the binding of cancer cells to 
tissues in the lung. This is important because such binding apparently 
enables cancerous cells to spread from one organ to another via the 
blood or other circulating body fluids.
The cancer cells used by the investigators in their experiments had 
spread to the lungs, but not to other organs in the body. But the 
investigators found that because binding to the target organ (the lung) 
is weak or very unstable in the presence of the pentapeptide, the 
cancer cells could not escape from the bloodstream.
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While swainsonine and the pentapeptide affect different steps 
required for the spread of cancer, both can prevent death caused by the 
dispersion of cancer to healthy parts of the body. For example, 
untreated mice died in 21-33 days following the intravenous injection 
of tumorous cells. But mice injected with tumorous cells and 
administered the pentapeptide showed no signs of lung cancer a year 
later.
It is therefore anticipated that swainsonine and the pentapeptide 
will have similar utility when used in humans. The researchers are 
now engaged in studies to determine if this anticipation is correct. If 
the two agents do prove to be effective in human cancers, the 
researchers will be ready to initiate clinical trials in patients upon 
completion of toxicological and pharmacological evaluation of the 
respective therapeutic agents.
This research is currently supported by grants awarded by the 
National Cancer Institute of the National Institutes of Health and the 
American Cancer Society. Articles describing the findings of the 
Howard research project include those published in the book 
Monoclonal Antibodies and Cancer Therapy (edited by R. Reisfeld and 
S. Sell, Alan R. Liss, Inc., New York, 1985) as well as recent issues of 
Proceedings National Academy o f Sciences, Science, Cancer Research, 
and Journal of the National Medical Association.
The thrust of this particular research, which requires the 
collaboration of basic scientists and clinicians, is what the authors of 
the National Cancer Act envisioned as an outgrowth of bringing 
together individuals from various disciplines into regional comprehen­
sive cancer research centers. Howard’s is one of 20 such centers in the 
United States. □
still associated with the use of monoclonal 
antibodies in cancer therapy, this experi­
mental approach will likely be useful in 
virtually all phases of management of the 
cancer patient.
It is important to realize that the above 
therapeutic approaches are still highly ex­
perimental. However, participation in 
clinical trials employing these therapies is 
strongly recommended if one’s cancer is 
known to be unresponsive to traditional 
treatments or has been diagnosed as in­
curable.
Clinical trials represent the best treat­
ment that medical science has to offer. 
However, the physician must consider a 
number of factors, such as age, general 
health, type and stage of cancer, and prior 
treatment before allowing a patient to 
participate in a clinical trial.
In summary, some new and exciting 
approaches to the treatment of cancer are 
currently being developed at several in­
stitutions across the country. While several 
of them show considerable promise, most 
may have been oversold by the news media, 
as was interferon a few years ago. Many 
cancer experts now fear that the recent 
publicity about interleukin-2 also may not 
be justified.
In any event, it is unlikely that a single 
“wonder drug” will cure all cancers. □
Kenneth Olden, Ph.D., is the director of the univer­
sity’s Cancer Center and professor and chairman, 
Department of Oncology, College of Medicine. 
Sandra L. White, Ph.D., is an associate professor 
in the Department of Microbiology, College of Med­
icine, and an associate member of the Immunology 
Program at the Cancer Center.
NEW DIRECTIONS OCTOBER 1987
